AusBioInvest 2023 programmelaunched24 Oct 2023Australia’s...

AusBioInvest 2023 programmelaunched

24 Oct 2023
Australia’s premier life science investmentconference unveils esteemed speaker line up and 26 Australian biotech companiespitching for partnerships.

The programme for AusBioInvest 2023 is now live,featuring an industry-led programme with thought-provoking keynote and panelsessions with leading investors and business leaders.

The programme includes a fireside chat withJennifer Nason, Global Chairman, Investment Banking, J.P. Morgan, who willprovide an update on global capital market trends, conditions and themes andwhat it means for Australian biotechs; Kanishka Pothula, Partner, Nextech, willparticipate in a fireside on considerations US investors make when evaluating adeal, with a focus on non-specialist investors navigating the sector; whileAjita Tynan, Manager, Listed Company Services, Australian Securities Exchange,will provide an update on the public markets in Australia.
In addition, AusBioInvest 2023 featurespresentation from 26 Australian biotech companies, spanning early- tolate-stage, that are actively seeking investors or partners to support theirfunding and co-development.

Presenting companies include: ArovellaTherapeutics (ASX:ALA), Avecho Biotechnology (ASX:AVE), BiomeBank, CarinaBiotech, Celosia Therapeutics, Cyban, Dimerix (ASX DXB), EBR Systems (ASX:EBR), Encapsolutions, ESFAM Biotech,FivepHusion, Genofax, Imagion Biosystems (ASX:IBX), Immuron Limited (ASX:IMC),InhaleRx (ASX:IRX), Invion (ASX: IVX), LBT Innovations (ASX:LBT), Microba(ASX:MAP), Noxopharm Limited (ASX:NOX), PolyActiva, Prescient Therapeutics(ASX TX), Respiri (ASX:RSH), Snoretox, TruScreen (ASX:TRU), TessaraTherapeutics, and Vaxxas.

AusBiotech CEO Lorraine Chiroiu says, “Access tocapital remains one of the biggest barriers for biotech companies in Australia.AusBioInvest fosters meaningful connections between the investment communityand investment-seeking life sciences companies, enabling great ideas to attractrisk-tolerant capital while assisting investors to connect with innovative,Australian companies that offer high-value return-on-investment.”

Stepping onto the stage of, AusBioInvest 2023,delegates can hear the latest insights and trends in life science investingfrom global and local experts, and make meaningful connections with leadinglocal biotech executives from publicly-listed and privately-owned companies asthey pitch their breakthrough health innovations to investors.

Held at the Parky Hyatt in Melbourne,AusBioInvest’s registered delegates represent Australia’s leading life sciencecompanies, and Australian and global investors representing venture capitalfirms, private equity firms, high net worth individuals, research analysts andbrokers, industry executives and major global stakeholders.

Qualified investors are invited to register fortheir complimentary pass today and to hear from their peers as well as thelatest from Australian innovators. Delegates that do not fit within theQualified Investor criteria are invited to register as an AusBioInvest 2023delegate.

Thank you to AusBiotech’s InvestmentAdvisory Group for their support in developing theprogramme.

Register for AusBioInvest 2023 here.